Online inquiry

IVTScrip™ mRNA-Anti-CTLA4, AGEN1884(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1877MR)

This product GTTS-WQ1877MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CTLA4 gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001037631.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1493
UniProt ID P16410
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CTLA4, AGEN1884(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ1877MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2599MR IVTScrip™ mRNA-Anti-MPL, AMG 531(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AMG 531
GTTS-WQ5075MR IVTScrip™ mRNA-Anti-CSF2RA, CAM-3001(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CAM-3001
GTTS-WQ4335MR IVTScrip™ mRNA-Anti-IL5RA, BIW-8405(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BIW-8405
GTTS-WQ4038MR IVTScrip™ mRNA-Anti-IL23A, BI 655066(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BI 655066
GTTS-WQ947MR IVTScrip™ mRNA-Anti-CD40, ABBV-323(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-323
GTTS-WQ15997MR IVTScrip™ mRNA-Anti-ERBB2, ZW-25(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ZW-25
GTTS-WQ11460MR IVTScrip™ mRNA-Anti-ERBB3, MEHD7945A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MEHD7945A
GTTS-WQ12233MR IVTScrip™ mRNA-Anti-CD274, MPDL3280A(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MPDL3280A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW